From Wikipedia, the free encyclopedia
Jump to: navigation, search
Clinical data
Routes of
ATC code
  • none
Legal status
Legal status
  • US: Unscheduled
Pharmacokinetic data
Biological half-life 1.6 hours
Excretion renal
CAS Number
PubChem CID
ECHA InfoCard 100.124.957
Chemical and physical data
Formula C12H15N
Molar mass 173.25 g/mol
3D model (Jmol)
 NYesY (what is this?)  (verify)

Bicifadine (DOV-220,075) is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) discovered at American Cyanamid as an analgesic drug candidate, and licensed to DOV Pharmaceutical in 1998 after American Cyanamid was acquired by Wyeth.[1][2][3]

In January 2007, Dov licensed the rights to bicifadine to XTL Biopharmaceuticals after bicifadine failed in a Phase III clinical trial for chronic lower back pain.[4][5][6] XTL ran a PhaseIIb clinical trial for pain caused by diabetic neuropathy, which failed in 2008;[7] XTL terminated the agreement in 2010.[8] In 2010 Dov was acquired by Euthymics Bioscience which intended to continue development of other candidates from Dov's portfolio.[9]

Bicifadine has a non-opioid, non-NSAID mechanism for the treatment of pain, which should have less abuse potential than opioid drugs and less propensity to cause gastric ulcers than NSAID drugs.[10] While the drug is purported to be a serotonin (SERT) and noradrenaline transporter (NET) inhibitor, it also has effects at the dopamine transporter (DAT), effectively making it a broad-spectrum monoamine transporter inhibitor or "triple reuptake inhibitor."[11]

See also[edit]


  1. ^ Marks DM, Pae CU, Patkar AA. Triple reuptake inhibitors: a premise and promise. Psychiatry Investig. 2008 Sep;5(3):142-7. PMID 20046357 PMC2796030
  2. ^ [ SEC Filing: Wyeth-DOV Restated License Agreement Page accessed July 15, 2015]
  3. ^ Neubauer, DN. "Indiplon". pp 453-464 in GABA and Sleep: Molecular, Functional and Clinical Aspects. Eds Jaime M. Monti, Seithikurippu Ratnas Pandi-Perumal, Hanns Möhler. Springer Science & Business Media, 2010 ISBN 9783034602266
  4. ^ BioCentury, July 26, 2010[full citation needed]
  5. ^ "Euthymics: Balancing act" (PDF). BioCentury, The Bernstein Report on Biobusiness. December 5, 2011. p. A13. 
  6. ^ John Caroll for Fierce Biotech. Jan 07, 2007 XTL licenses development rights to pain therapy
  7. ^ Fierce Biotech. December 9, 2008 Tiny XTL cuts costs, jobs
  8. ^ XTL Form 6-K March, 2013
  9. ^ Fierce Biotech July 22, 2010 Euthymics lands $24M to fund antidepressant work
  10. ^ Wang, R. I.; Johnson, R. P.; Lee, J. C.; Waite, E. M. (1982). "The Oral Analgesic Efficacy of Bicifadine Hydrochloride in Postoperative Pain". Journal of Clinical Pharmacology. 22 (4): 160–164. doi:10.1002/j.1552-4604.1982.tb02157.x. PMID 7096604. 
  11. ^ Basile, A.; Janowsky, A.; Golembiowska, K.; Kowalska, M.; Tam, E.; Benveniste, M.; Popik, P.; Nikiforuk, A.; Krawczyk, M.; Nowak, G.; Krieter, P. A.; Lippa, A. S.; Skolnick, P.; Koustova, E. (2007). "Characterization of the Antinociceptive Actions of Bicifadine in Models of Acute, Persistent, and Chronic Pain". The Journal of Pharmacology and Experimental Therapeutics. 321 (3): 1208–1225. doi:10.1124/jpet.106.116483. PMID 17325229.